Boston Scientific Corp (BSX) Shares Hovering Above Chikou

Joanna Estrada
November 14, 2017

American International Group Inc says it sold 21,527 shares last quarter decreasing its holdings in Boston Scientific Corp by 5.0%. The number of shares now owned by investors are 109.8 mln. The value of the investment in Boston Scientific Corp decreased from $11,937,000 to $11,934,000 a change of 0.0% since the last quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Amalgamated Bank expanded its investment by buying 3,580 shares an increase of 2.2% as of 09/30/2017. Prudential Financial Inc. now owns 4,762,674 shares of the medical equipment provider's stock worth $138,928,000 after buying an additional 2,850,630 shares in the last quarter. Bronfman E.L. Rothschild L.P. raised its position in Boston Scientific Corporation by 14.3% in the 2nd quarter. Jennison Associates LLC lifted its stake in shares of Boston Scientific Corporation by 405.3% in the second quarter. The RSI may be more volatile using a shorter period of time. Sivik Global Healthcare LLC now controls 260,000 shares worth $7,584,000. Following the transaction, the executive vice president now directly owns 185,742 shares in the company, valued at approximately $5,100,475.32. The stock ended last trade at $28.45 a share and the price is up more than 31.53% so far this year. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

In other Boston Scientific Corporation news, EVP Timothy A. Pratt sold 10,104 shares of the stock in a transaction that occurred on Friday, September 1st.

Moving average convergence divergence (MACD) shows that the stock is on a PRICE RELATIVITY trend. The disclosure for this sale can be found here. Insiders own 1.31% of the company's stock.

The company is down by 0.14% since yesterday's close of 28.36. Over the past five trading sessions it is 2.3%; -3.36% for the month; 7.48% for the last quarter; 7.44% for the past six-months; and 32.33% for the last 12 months. The company has a quick ratio of 0.50, a current ratio of 0.72 and a debt-to-equity ratio of 0.58. Boston Scientific Corp. has a one year low of $15.67 and a one year high of $24.79. Boston Scientific Corp now has a P/E ratio of 46.71 and the market cap is 38.88B. Boston Scientific Corporation's quarterly revenue was up 5.6% compared to the same quarter last year. research analysts anticipate that Boston Scientific Corporation will post 1.25 EPS for the current fiscal year. Bellevue Group AG bought a new position in Boston Scientific Corp. during the first quarter worth $9,405,000. The firm had revenue of $2.22 billion for the quarter, compared to analysts' expectations of $2.21 billion. The 1 year EPS growth rate is 27.10%. If you are viewing this report on another site, it was stolen and reposted in violation of United States and worldwide trademark and copyright law.

Currently, the 14-day ADX for Boston Scientific Corp (BSX) is sitting at 36.04. Also, the Hold rating count is 2 as of 11/13/17. Royal Bank Of Canada reaffirmed a "buy" rating and issued a $31.00 price objective on shares of Boston Scientific Corporation in a research note on Tuesday, November 7th. SunTrust Banks, Inc. set a $34.00 price objective on Boston Scientific Corporation and gave the company a "buy" rating in a research note on Tuesday, October 31st. Canaccord Genuity released research on BSX with an initial rating of "Buy".

October 13 investment analysts at BMO Capital Markets held the stock rating at "Buy" targeting a price of $30.00.

Boston Scientific Corporation is a worldwide developer, manufacturer and marketer of minimally invasive medical devices. The company's products are used in a broad range of interventional medical specialties, including cardiology, electrophysiology, gastroenterology, neuro-endovascular therapy, pulmonary medicine, radiology, urology and vascular surgery.

Other reports by Click Lancashire

Discuss This Article